ACRO BIOMEDICAL CO., LTD. (ACBM) Stock & Financials
ACRO BIOMEDICAL CO., LTD. (ACBM) is a company.
What to check next
For informational purposes only. Not investment advice. Data may be delayed or inaccurate; verify independently. The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results. Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing.
ACRO BIOMEDICAL CO., LTD. Financial Health ScoreFY2025
Weak financial health; requires careful evaluation
0 pts YoYThis Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- Altman Z-Score -2022.17 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Accrual-heavy earnings: Net income significantly exceeds operating cash flow
Data sourced from SEC EDGAR filings. Not investment advice.
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
About ACRO BIOMEDICAL CO., LTD.
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Profitability Data Under ReviewProfitability metrics are being verified. Some SEC filing data may require additional validation.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
Balance Sheet Data LimitedInsufficient data to assess financial health.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
ACRO BIOMEDICAL CO., LTD. 4-Year Revenue, Profit & Cash Flow History
Annual Financials
FY2025 - FY2022| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0(-100.0%) | $658,500 |
| Net Income | $-101,146(-139.1%) | $-42,297(+99.5%) | $-8,807,573(+44.5%) | $-15,871,443 |
| Total Assets | $14,098 | $31,974 | $58,459 | $687,486 |
| Total Debt | - | - | - | - |
| Total Equity | $-386,964 | $-294,972 | $-257,014 | $486,370 |
| Profit Margin | - | - | - | -2410.2% |
| ROE | - | - | - | -3263.2% |
| ROA | -717.5% | -132.3% | -15066.2% | -2308.6% |
Quarterly Financials
Last 8 quarters| Metric | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $298,500 |
| Net Income | $-10,301 | $-11,252 | $-11,252 | $-11,252 | $-4,004,354 | $-4,004,354 | $-4,004,354 | $-3,928,797 |
| Total Assets | $14,098 | $31,974 | $31,974 | $31,974 | $58,459 | $58,459 | $58,459 | $687,486 |
Insider Trading
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
ACRO BIOMEDICAL CO., LTD. Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
ACRO BIOMEDICAL CO., LTD. FAQ
Does ACRO BIOMEDICAL CO., LTD. pay dividends?
No, ACRO BIOMEDICAL CO., LTD. (ACBM) does not currently pay dividends to shareholders.
What is ACRO BIOMEDICAL CO., LTD.'s financial health score?
ACRO BIOMEDICAL CO., LTD. has a financial health score of 16/100 (Grade: F), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of ACRO BIOMEDICAL CO., LTD. financial data are available?
4 years of financial data are available for ACRO BIOMEDICAL CO., LTD. from FY2022 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.